Search results
Results From The WOW.Com Content Network
Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma , autoimmune diseases and prostate cancer .
Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. In humans, it is encoded by the IL6 gene. [5] In addition, osteoblasts secrete IL-6 to stimulate osteoclast formation. Smooth muscle cells in the tunica media of many blood vessels also produce IL-6 as a pro-inflammatory cytokine.
Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. [ 1 ] Hence, anti-IL6 agents have been sought.
In order to generate a molecular tool to discriminate between Interleukin-6 classic signaling and Interleukin-6 trans-signaling, a cDNA coding for human Interleukin-6 and a cDNA coding for the human soluble Interleukin-6 receptor were connected by a cDNA coding for a 13 amino acids long linker, which was long enough to bridge the 40 Å distance between the COOH terminus of the soluble ...
IL-2 receptor; Interleukin-3 receptor; Interleukin-4 receptor; Interleukin-5 receptor; Interleukin-6 receptor; Interleukin-7 receptor; Interleukin-7 receptor-α; Interleukin-9 receptor; Interleukin-11 receptor; Interleukin-12 receptor; Interleukin-13 receptor; Interleukin-15 receptor; Interleukin-21 receptor; Interleukin-23 receptor ...
It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). [18] Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
Glycoprotein 130 (also known as gp130, IL6ST, IL6R-beta or CD130) is a transmembrane protein which is the founding member of the class of tall cytokine receptors.It forms one subunit of the type I cytokine receptor within the IL-6 receptor family.
Olokizumab is the first interleukin-6 (IL-6) inhibitor approved for treatment of rheumatoid arthritis which blocks directly cytokine instead of its receptor. [1] Olokizumab specifically binds to IL-6 at Site 3, blocking IL-6 ability to form hexameric complex. [2] Olokizumab was developed by R-Pharm group, and was launched in 2020. [3]